Baqir Lakhani, DO
Advanced Heart Failure and Transplant Cardiology · Elk Grove Village, ILNPI 1750677043
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,490 of the $5,628 with a category attached, or 62.0%. 22 manufacturers reported payments, led by Abiomed at 33.2% of the total. Reporting peaked in 2019 at $2,690 and has fallen 74.6% since, to $684 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in IL, where the typical reported total is $11,038.
Across 129 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Abbott$2K
- Novartis$244
- Boehringer Ingelheim$201
- Alnylam Pharmaceuticals Inc.$173
- Medtronic$170
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$1,50027%
- Travel & lodging$62311%
- Food & beverage$3,49062%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 5 | $1,868 |
| Abbott | 54 | $1,828 |
| Novartis | 12 | $244 |
| Boehringer Ingelheim | 7 | $201 |
| Alnylam Pharmaceuticals Inc. | 6 | $173 |
| Medtronic(2 entities) | 3 | $170 |
| AstraZeneca | 7 | $159 |
| W. L. Gore & Associates, Inc. | 4 | $138 |
| Boston Scientific | 3 | $111 |
| Merck | 5 | $107 |
| Livanova USA, Inc. | 1 | $104 |
| Ancora Heart, Inc. | 2 | $81 |
| Scpharmaceuticals Inc. | 3 | $77 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $73 |
| Cvrx, Inc. | 4 | $56 |
| Kestra Medical Technology Services, Inc. | 1 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Pfizer | 1 | $33 |
| Johnson & Johnson | 1 | $32 |
| Bayer | 1 | $29 |
| Daxor Corporation | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,755
- HeartMate 3 Left Ventricular Dev$683
- CARDIOMEMS$223
- HeartWare HVAD$112
- LifeSPARC$104
How this compares
$5,628 in reported general payments places this provider in the 20th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $492,668 |
| EntrestoSacubitril/Valsartan | 188 | $265,892 |
| VyndaqelTafamidis Meglumine | 11 | $245,209 |
| JardianceEmpagliflozin | 143 | $171,160 |
| EliquisApixaban | 37 | $47,249 |
| FarxigaDapagliflozin Propanediol | 38 | $40,266 |
| XareltoRivaroxaban | 14 | $12,706 |
| Bumetanide | 57 | $3,091 |
| Metoprolol Succinate | 157 | $2,078 |
| Torsemide | 30 | $1,486 |
| Eplerenone | 14 | $1,449 |
| Spironolactone | 169 | $1,408 |
| Potassium Chloride | 70 | $1,140 |
| Hydralazine Hcl | 50 | $758 |
| Furosemide | 99 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $33 | $785,12570 claims |
| NovartisEntresto | $244 | $265,892188 claims |
| Boehringer IngelheimJardiance | $201 | $171,160143 claims |
| AstraZenecaFarxiga | $159 | $40,26638 claims |
| Johnson & JohnsonXarelto | $32 | $12,70614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Elk Grove Village
- Ashish HaryaniElk Grove Village$38K
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
- Bow ChungChicago$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.